Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks

References

• Patrono C, Baigent C. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol Interv. 2009;9:31–39.
   PubMedGoogle Scholar
• Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.
   PubMedGoogle Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.
   PubMed Web of Science ®Google Scholar
• Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43:1262–1275. doi:10.1111/apt.13642.
   PubMed Web of Science ®Google Scholar
• Yang M, Wang HT, Zhao M, et al. Network meta-analysis comparing relatively selective COX-2 inhibitors versus coxibs for the prevention of NSAID-induced gastrointestinal injury. Medicine (Baltimore). 2015;94:e1592. doi:10.1097/MD.0000000000001592.
   PubMed Web of Science ®Google Scholar
• van Walsem A, Pandhi S, Nixon RM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015;17:66. doi:10.1186/s13075-015-0554-0.
   PubMed Web of Science ®Google Scholar
• Essex MN, Zhang RY, Berger MF, et al. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Saf. 2013;12:465–477. doi:10.1517/14740338.2013.780595.
   PubMed Web of Science ®Google Scholar
• Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48:830–838. doi:10.1007/s00535-012-0717-6.
   PubMed Web of Science ®Google Scholar
• Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15:R6. doi:10.1186/ar4134.
   PubMed Web of Science ®Google Scholar
• Rostom A, Muir K, Dube C, et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf. 2009;1:47–71. [Epub 2009 Oct 28].
   PubMedGoogle Scholar
• Coxib and traditional NSAID Trialist’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomized trials. Lancet. 2013;382:769–779.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–1080.
   PubMed Web of Science ®Google Scholar
• Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163:481–486.
   PubMed Web of Science ®Google Scholar
• Nissen SE. Cox-2 inhibitors and cardiovascular disease: considerable heat, but not much light. Eur Heart J. 2012;33:2631–2633.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280–2288.
   PubMed Web of Science ®Google Scholar
• Weir MR, Sperling RS, Reicin A, et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146:591–604.
   PubMed Web of Science ®Google Scholar
• Aldington S, Shirtcliffe P, Weatherall M, et al. Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy. N Z Med J. 2005;118:U1684.
   PubMedGoogle Scholar
• Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7:R644–65.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–1308.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Gregor P, Ormiston TM, et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med. 2006;119:552–559.
   PubMed Web of Science ®Google Scholar
• Curtis SP, Ko AT, Bolognese JA, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22:2365–2374.
   PubMed Web of Science ®Google Scholar
• Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99:132–140.
   PubMed Web of Science ®Google Scholar
• White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91–98.
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007;16:762–772.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Wittes J, Finn PV, et al. For the cross trial safety assessment group. cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104–2113.
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1–278.
   PubMed Web of Science ®Google Scholar
• Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data. Arch Intern Med. 2009;169:1976–1985.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal ant-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal ant-inflammatory drugs: a meta-analysis. Arthritis Res Ther. 2006;8:R153.
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266–274.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633–1644.
   PubMed Web of Science ®Google Scholar
• Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021–2029.
   PubMed Web of Science ®Google Scholar
• Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007;66:1296–1304.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22:559–570.
   PubMed Web of Science ®Google Scholar
• Ray WA. Cardiovascular safety of NSAIDs. BMJ. 2011;342:c6618.
   PubMed Web of Science ®Google Scholar
• Salvo F, Fourrier-Réglat A, Bazin F, et al. Investigators of safety of non-steroidal anti-inflammatory drugs: SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89:855–866.
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–1642.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal anti-inflammatory drugs and risk of incident heart failure: a systematic review and meta-analysis of observational studies. Clin Cardiol. 2016;39:111–118.
   PubMed Web of Science ®Google Scholar
• Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007;370:2138–2151.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Kitas GD, Carroll D. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res Ther. 2012;14:R117. doi:10.1186/ar3847.
   PubMed Web of Science ®Google Scholar
• Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319–329. doi:10.1016/j.arr.2010.11.002.
   PubMed Web of Science ®Google Scholar
• Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology (Oxford). 2010;49:536–541. doi:10.1093/rheumatology/kep393.
   PubMed Web of Science ®Google Scholar
• Tarp S, Bartels EM, Bliddal H, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012;64:3511–3521. doi:10.1002/art.34644.
   PubMed Web of Science ®Google Scholar
• Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921–1925. doi:10.1136/ard.2011.151191.
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Brookhart AM, Symmons DP, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009;68:367–372. doi:10.1136/ard.2007.076760.
   PubMed Web of Science ®Google Scholar
• Franklin J, Farragher TM, Lunt M, et al. Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. Ann Rheum Dis. 2010;69:1660–1664. doi:10.1136/ard.2009.121871.
   PubMed Web of Science ®Google Scholar
• Fischer LM1, Schlienger RG, Matter CM, et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med. 2004;164:2472–2476.
   PubMed Web of Science ®Google Scholar
• Fischer LM, Schlienger RG, Matter C, et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004;93:198–200.
   PubMed Web of Science ®Google Scholar
• Schlienger RG1, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol. 2002;54:327–332.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis. 2005;64:1539–1541.
   PubMed Web of Science ®Google Scholar
• Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. 2014;9:e91286. doi:10.1371/journal.pone.0091286.
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Bartle B, et al. Osteoarthritis: a comorbid marker for longer life? Ann Epidemiol. 2007;17:380–384.
   PubMed Web of Science ®Google Scholar
• Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med. 2007;120:98.e9–e16.
   Web of Science ®Google Scholar
• Mangoni AA, Woodman RJ, Gaganis P, et al. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol. 2010;69:689–700. doi:10.1111/j.1365-2125.2010.03627.x.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Reid DM Knights KM. Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: where do we stand? Age Ageing. 2010;39:530–533. doi:10.1093/ageing/afq099.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628–1636. doi:10.1016/j.jacc.2008.08.041.
   PubMed Web of Science ®Google Scholar
• Chan AT, Sima CS, Zauber AG, et al. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011;4:1172–1180. doi:10.1158/1940-6207.CAPR-10-0403.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–684.
   PubMed Web of Science ®Google Scholar
• Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162:1105–1110.
   PubMed Web of Science ®Google Scholar
• Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73:1515–1521. DOI:10.1136/annrheumdis-2012-203137.
   PubMed Web of Science ®Google Scholar
• Curfman GD, Morrissey S, Drazen JM: Expression of concern: Bombardier et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Web site. Arthritis Advisory Committee. Drug Safety and Risk Management Advisory Committee; [cited 2014 Feb 10–11]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm383191.pdf.
   Google Scholar
• Gupta M, Singh N, Tsigoulis M, et al. Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol. 2012;28:14–19.
   PubMed Web of Science ®Google Scholar
• Gadzhanova S, Ilomäki J, Roughead EE. COX-2 inhibitor and non-selective NSAID use in those at increased risk of NSAID-related adverse events: a retrospective database study. Drugs Aging. 2013;30:23–30.
   PubMed Web of Science ®Google Scholar
• Sajadieh A, Wendelboe O, Hansen JF, et al. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial. Am J Cardiol. 1999;83:1263–1265.
   PubMed Web of Science ®Google Scholar
• Ko D, Wang Y, Berger AK, et al. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J. 2002;143:475–481.
   PubMed Web of Science ®Google Scholar
• Barthélémy O, Limbourg T, Collet JP, et al. Impact of non-steroidal ant-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol. 2013;163:266–271.
   PubMed Web of Science ®Google Scholar
• Stürmer T, Schneeweiss S, Brookhart MA, et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161:891–898.
   PubMed Web of Science ®Google Scholar
• Vanasse A, de Brum-Fernandes AJ, Courteau J. Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study. Heart Int. 2009;4:e10.
   PubMedGoogle Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal anti-inflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2:155–163.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–3006.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Maeng M, et al. Nonsteroidal antiinflammatory drug use and cardiovascular risks after coronary stent implantation. Pharmacotherapy. 2011;31:458–468.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068–2073.
   PubMed Web of Science ®Google Scholar
• Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. Cmaj. 2006;174:1563–1569.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Web site. Arthritis Advisory Committee. Drug Safety and Risk Management Advisory Committee; [updated 2014 Feb 10–11; cited 2014 May 14]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm380874.htm.
   Google Scholar
• Chan AT, Manson JE, Albert CM, et al. Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113:1578–1587.
   PubMed Web of Science ®Google Scholar
• van Sijl AM, Boers M, Voskuyl AE, et al. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One. 2014;9:e87965.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Abrahamowicz M, De Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52:68–75.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170:1968–1976.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010;170:1979–1986.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Flowers N, Burke TA, et al. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 2002;29:1015–1022.
   PubMed Web of Science ®Google Scholar
• Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9:199–205.
   PubMedGoogle Scholar
• Lipworth L, Friis S, Mellemkjaer L, et al. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol. 2003;56:796–801.
   PubMed Web of Science ®Google Scholar
• Ekström N, Cederholm J, Zethelius B, et al. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open. 2013;3:pii: e002688. Print 2013. DOI10.1136/bmjopen-2013-002688.
   Web of Science ®Google Scholar
• Odom DM, Mladsi DM, Saag KG, et al. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literature reviews. Clin Ther. 2014 May 23:pii: S0149–S2918. (14)00210-0. DOI:10.1016/j.clinthera.2014.04.012. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Katz JA. COX-2 inhibition: what we learned – a controversial update on safety data. Pain Med. 2013;14(Suppl 1):S29–S34.
   PubMed Web of Science ®Google Scholar
• Fowler PD. Aspirin, paracetamol and non-steroidal anti-inflammatory drugs. A comparative review of side effects. Med Toxicol Adverse Drug Exp. 1987;2:338–366.
   PubMedGoogle Scholar